Necrosis in breast cancer patients with skin metastases receiving bevacizumab-based therapy

Journal of Wound Care

Volumn 20, Issue 9, 2011, Pages 403-410

  Cottu, P H ^a   Fourchotte, V ^b   Vincent Salomon, A ^c   Kriegel, I ^d   Fromantin, I ^e,f  

^a Departments of Medical Oncology Gustave Roussy Cancer Campus   (France)

^b Departments of Surgical Oncology   (France)

^c Departments of Pathology and Tumour Biology   (France)

^d Departments of Anesthesiology   (France)

^e INSTITUT CURIE   (France)

^f UNIVERSITÉ DE CERGY PONTOISE   (France)

Author keywords

Bevacizumab; Breast cancer; Erosive skin lesions; Metastases

Indexed keywords

EID: 80052620343     PISSN: 09690700     EISSN: None     Source Type: Journal    
DOI: 10.12968/jowc.2011.20.9.403     Document Type: Article

References (21)

1. Banerjee, S., Dowsett, M., Ashworth, A., Martin, L.A. Mechanisms of disease: angiogenesis and the management of breast cancer. Nat Clin Pract Oncol. 2007; 4:9, 536-550. (Pubitemid 47351464)
2. Schneider, B.P., Miller, K.D. Angiogenesis of breast cancer. J Clin Oncol. 2005; 23:8, 1782-1790. (Pubitemid 46211430)
3. Miller, K., Wang, M., Gralow, J. et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med. 2007; 357:26, 2666-2676.
4. Miles, D., Chan, A., Romieu, G. et al. Randomized, double-blind, placebo-controlled, phase III study of bevacizumab with docetaxel or docetaxel with placebo as first-line therapy for patients with locally recurrent or metastatic breast cancer (mBC): AVADO.J Clin Oncol. 2008; 26: abstr LBA1011.
5. Fox, S.B., Generali, D.G., Harris, A.L. Breast tumour angiogenesis. Breast Cancer Res. 2007; 9:6, 216.
6. Kim, K.J., Li, B., Winer, J. et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature. 1993; 362: 6423, 841-844. (Pubitemid 23132159)
7. Sweeney, C.J., Miller, K.D., Sissons, S.E. et al. The antiangiogenic property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular endothelial growth factor or 2-methoxyestradiol but antagonized by endothelial growth factors. Cancer Res. 2001; 61:8, 3369-3372. (Pubitemid 32695027)
8. Hurwitz, H., Saini, S. Bevacizumab in the treatment of metastatic colorectal cancer: safety profile and management of adverse events. Semin Oncol. 2006; 33:5 (Suppl. 10), S26-S34. (Pubitemid 44634007)
9. Burkart, C.M., Grisel, J.J., Horn, D.B. Spontaneous nasal septal perforation with antiangiogenic bevacizumab therapy. Laryngoscope. 2008; 118: 9, 1539-1541.
10. Ruiz, N., Fernandez-Martos, C., Romero, I. et al. Invasive fungal infection and nasal septum perforation with bevacizumab-based therapy in advanced colon cancer. J Clin Oncol. 2007; 25:22, 3376-3377. (Pubitemid 47325627)
11. Staudacher, L., Cottu, P.H., Dieras, V. et al. Platinum-based chemotherapy in metastatic triple-negative breast cancer: the Institut Curie experience. Ann Oncol. 2011;22:4, 848-856.
12. Grocott, P. Care of patients with fungating malignant wounds. Nurs Stand. 2007; 21:24, 57-58, 60, 62 passim.
13. Lazzati, V., Zygon, J., Lohsiriwat, V. et al. Impaired wound healing and bilateral mastectomy flap necrosis in a patient with locally advanced breast cancer after neoadjuvant Paclitaxel with bevacizumab. Aesthetic Plast Surg. 2010; 34:6, 796-797.
14. Goyal, S., Rao, M.S., Khan, A. et al. Evaluation of acute locoregional toxicity in patients with breast cancer treated with adjuvant radiotherapy in combination with bevacizumab. Int J Radiat Oncol Biol Phys. 2011;79: 2, 408-413.
15. Bose, D., Meric-Bernstam, F., Hofstetter, W. et al. Vascular endothelial growth factor targeted therapy in the perioperative setting: implications for patient care. Lancet Oncol. 2010; 11:4, 373-382.
16. Mellor, J.D., Cassumbhoy, M., Jefford, M. Clinical guidance on the perioperative use of targeted agents in solid tumor oncology. Asia Pac J Clin Oncol. 2011;7:2, 106-113.
17. Pignot, G., Lebret, T., Chekulaev, D. et al. Healing and targeted therapies: management in perioperative period? (in French). Prog Urol. 2011; 21:3, 166-172.
18. Ebos, J.M.L., Lee, C.R., Cruz-Munoz, W. et al. Accelerated Metastasis after Short-Term Treatment with a Potent Inhibitor of Tumor Angiogenesis. Cancer Cell. 2009; 15:3, 232-239
19. Paez-Ribes, M., Allen, E., Hudock, J. et al. Antiangiogenic Therapy Elicits Malignant Progression of Tumors to Increased Local Invasion and Distant Metastasis. Cancer Cell. 2009; 15:3, 220-231.
20. Reynolds, A.R., Hart, I.R., Watson, A.R. et al. Stimulation of tumor growth and angiogenesis by low concentrations of RGD-mimetic integrin inhibitors. Nat Med. 2009; 15:4, 392-400.
21. Bao, P., Kodra, A., Tomic-Canic, M. et al. The role of vascular endothelial growth factor in wound healing. J Surg Res. 2009; 153:2, 347-358.